DMAC
Price
$4.16
Change
+$0.07 (+1.71%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
177.54M
61 days until earnings call
HMTXF
Price
$0.09
Change
-$0.00 (-0.00%)
Updated
Jun 3 closing price
Capitalization
12.21M
Interact to see
Advertisement

DMAC vs HMTXF

Header iconDMAC vs HMTXF Comparison
Open Charts DMAC vs HMTXFBanner chart's image
DiaMedica Therapeutics
Price$4.16
Change+$0.07 (+1.71%)
Volume$1.92K
Capitalization177.54M
Hemostemix
Price$0.09
Change-$0.00 (-0.00%)
Volume$51K
Capitalization12.21M
DMAC vs HMTXF Comparison Chart
Loading...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DMAC vs. HMTXF commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMAC is a StrongBuy and HMTXF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (DMAC: $4.09 vs. HMTXF: $0.09)
Brand notoriety: DMAC and HMTXF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DMAC: 108% vs. HMTXF: 176%
Market capitalization -- DMAC: $177.54M vs. HMTXF: $12.21M
DMAC [@Biotechnology] is valued at $177.54M. HMTXF’s [@Biotechnology] market capitalization is $12.21M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DMAC’s FA Score shows that 0 FA rating(s) are green whileHMTXF’s FA Score has 1 green FA rating(s).

  • DMAC’s FA Score: 0 green, 5 red.
  • HMTXF’s FA Score: 1 green, 4 red.
According to our system of comparison, HMTXF is a better buy in the long-term than DMAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DMAC’s TA Score shows that 5 TA indicator(s) are bullish.

  • DMAC’s TA Score: 5 bullish, 3 bearish.

Price Growth

DMAC (@Biotechnology) experienced а -2.39% price change this week, while HMTXF (@Biotechnology) price change was +48.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.92%. For the same industry, the average monthly price growth was +17.56%, and the average quarterly price growth was +3.51%.

Reported Earning Dates

DMAC is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+11.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DMAC($178M) has a higher market cap than HMTXF($12.2M). HMTXF YTD gains are higher at: 18.192 vs. DMAC (-24.678). HMTXF has higher annual earnings (EBITDA): -1.96M vs. DMAC (-24.07M). DMAC has more cash in the bank: 50.2M vs. HMTXF (63.3K). DMAC has less debt than HMTXF: DMAC (365K) vs HMTXF (4.77M). DMAC (0) and HMTXF (0) have equivalent revenues.
DMACHMTXFDMAC / HMTXF
Capitalization178M12.2M1,459%
EBITDA-24.07M-1.96M1,230%
Gain YTD-24.67818.192-136%
P/E RatioN/AN/A-
Revenue00-
Total Cash50.2M63.3K79,305%
Total Debt365K4.77M8%
FUNDAMENTALS RATINGS
DMAC vs HMTXF: Fundamental Ratings
DMAC
HMTXF
OUTLOOK RATING
1..100
1958
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
4
Undervalued
PROFIT vs RISK RATING
1..100
95100
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
5938
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HMTXF's Valuation (4) in the null industry is somewhat better than the same rating for DMAC (61) in the Biotechnology industry. This means that HMTXF’s stock grew somewhat faster than DMAC’s over the last 12 months.

DMAC's Profit vs Risk Rating (95) in the Biotechnology industry is in the same range as HMTXF (100) in the null industry. This means that DMAC’s stock grew similarly to HMTXF’s over the last 12 months.

DMAC's SMR Rating (94) in the Biotechnology industry is in the same range as HMTXF (100) in the null industry. This means that DMAC’s stock grew similarly to HMTXF’s over the last 12 months.

HMTXF's Price Growth Rating (38) in the null industry is in the same range as DMAC (59) in the Biotechnology industry. This means that HMTXF’s stock grew similarly to DMAC’s over the last 12 months.

HMTXF's P/E Growth Rating (100) in the null industry is in the same range as DMAC (100) in the Biotechnology industry. This means that HMTXF’s stock grew similarly to DMAC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DMAC
RSI
ODDS (%)
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 9 days ago
83%
Declines
ODDS (%)
Bearish Trend 16 days ago
82%
BollingerBands
ODDS (%)
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CLBEX35.68N/A
N/A
American Funds American Balanced 529E
GMAZX16.60N/A
N/A
GMO International Opportunistic Val IV
PXIIX21.69N/A
N/A
Virtus KAR Equity Income I
JCAVX9.33N/A
N/A
JHFunds2 Capital Appreciation Value NAV
ELFNX88.65-0.05
-0.06%
Elfun Trusts

DMAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with WHWK. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then WHWK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
-2.62%
WHWK - DMAC
43%
Loosely correlated
-0.59%
HUMA - DMAC
31%
Poorly correlated
-0.38%
ELDN - DMAC
30%
Poorly correlated
-6.15%
VTGN - DMAC
30%
Poorly correlated
-0.84%
SYRE - DMAC
29%
Poorly correlated
+0.54%
More

HMTXF and

Correlation & Price change

A.I.dvisor tells us that HMTXF and DMAC have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HMTXF and DMAC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HMTXF
1D Price
Change %
HMTXF100%
N/A
DMAC - HMTXF
22%
Poorly correlated
-2.62%
BIVI - HMTXF
21%
Poorly correlated
-0.46%
AGEN - HMTXF
21%
Poorly correlated
-8.35%
DVHGF - HMTXF
21%
Poorly correlated
N/A
FDMT - HMTXF
12%
Poorly correlated
+2.09%
More